GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Synlogic Inc (NAS:SYBX) » Definitions » Operating Margin %

SYBX (Synlogic) Operating Margin % : 0.00% (As of Mar. 2025)


View and export this data going back to 2015. Start your Free Trial

What is Synlogic Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Synlogic's Operating Income for the three months ended in Mar. 2025 was $-0.86 Mil. Synlogic's Revenue for the three months ended in Mar. 2025 was $0.00 Mil. Therefore, Synlogic's Operating Margin % for the quarter that ended in Mar. 2025 was 0.00%.

Warning Sign:

Synlogic Inc operating margin has been in a 5-year decline. The average rate of decline per year is -61.2%.

The historical rank and industry rank for Synlogic's Operating Margin % or its related term are showing as below:


SYBX's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -117.115
* Ranked among companies with meaningful Operating Margin % only.

Synlogic's 5-Year Average Operating Margin % Growth Rate was -61.20% per year.

Synlogic's Operating Income for the three months ended in Mar. 2025 was $-0.86 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2025 was $-6.08 Mil.


Synlogic Operating Margin % Historical Data

The historical data trend for Synlogic's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Synlogic Operating Margin % Chart

Synlogic Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -11,094.68 -3,464.37 -5,713.47 -1,636.34 -197,212.50

Synlogic Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -131,950.00 - - - -

Competitive Comparison of Synlogic's Operating Margin %

For the Biotechnology subindustry, Synlogic's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Synlogic's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Synlogic's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Synlogic's Operating Margin % falls into.


;
;

Synlogic Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Synlogic's Operating Margin % for the fiscal year that ended in Dec. 2024 is calculated as

Operating Margin %=Operating Income (A: Dec. 2024 ) / Revenue (A: Dec. 2024 )
=-15.777 / 0.008
=-197,212.50 %

Synlogic's Operating Margin % for the quarter that ended in Mar. 2025 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2025 ) / Revenue (Q: Mar. 2025 )
=-0.858 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Synlogic  (NAS:SYBX) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Synlogic Operating Margin % Related Terms

Thank you for viewing the detailed overview of Synlogic's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Synlogic Business Description

Traded in Other Exchanges
Address
PO Box 30, Winchester, MA, USA, 01890
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.
Executives
Antoine Awad officer: Chief Operating Officer C/O SYNLOGIC, INC., 301 BINNEY STREET, SUITE 402, CAMBRIDGE MA 02142
Michael Vangsted Jensen officer: Chief Financial Officer 301 BINNEY STREET, SUITE 402, CAMBRIDGE MA 02142
Aoife Brennan officer: Chief Medical Officer 200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139
Lisa Kelly-croswell director C/O SYNLOGIC, INC., 301 BINNEY STREET, SUITE 402, CAMBRIDGE MA 02142
Michael Thomas Heffernan director C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Michael F. Burgess director C/O SYNLOGIC, INC., 301 BINNEY STREET, SUITE 402, CAMRIDGE MA 02142
Richard P Shea director C/O MOMENTA PHARMACEUTICALS, INC., 43 MOULTON STREET, CAMBRIDGE MA 02138
Gregg Beloff officer: See Remarks C/O CERULEAN PHARMA INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Richard J. Riese officer: Chief Medical Officer C/O SYNLOGIC, INC., 301 BINNEY STREET, SUITE 402, CAMBRIDGE MA 02142
Ginkgo Bioworks, Inc. 10 percent owner 27 DRYDOCK AVENUE, 8TH FLOOR, BOSTON MA 02210
Scott Eric Plevy officer: Chief Scientific Officer 301 BINNEY STREET, #402, C/O SYNLOGIC, INC., CAMBRIDGE MA 02142
Paul Francis Miller officer: Chief Scientific Officer 200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139
Patricia N. Hurter director C/O SYNLOGIC, INC., 301 BINNEY ST., SUITE 402, CAMBRIDGE MA 02142
Andrew Gengos officer: See Remarks 21900 BURBANK BOULEVARD, 3RD FLOOR, WOODLAND HILLS CA 91367
Todd Shegog officer: See Remarks 200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139

Synlogic Headlines

From GuruFocus

Synlogic Inc Annual Shareholders Meeting Transcript

By GuruFocus Research 02-09-2024

Q3 2021 Synlogic Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q1 2021 Synlogic Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Synlogic Inc at Chardan Leadership Call Transcript

By GuruFocus Research 02-09-2024

Q2 2020 Synlogic Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q1 2019 Synlogic Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q4 2020 Synlogic Inc Earnings Call Transcript

By GuruFocus Research 02-09-2024

Synlogic Inc Phase 2 Announcement Call Transcript

By GuruFocus Research 02-09-2024